Biocon Biologics Expands Access to Biosimilars In Over 30 Countries In Africa and Asia
By EsqSocial Corporation 05/02/21
Biocon Biologics, a subsidiary of Biocon, announced today that it has signed an agreement with Clinton Health Access Initiative (CHAI) to develop advanced cancer therapies for patients in 25 countries in Africa and 5 countries in Asia as part of the Cancer Access Partnership (CAP). According to the announcement, Biocon Biologics aims to offer affordable biosimilars, initially trastuzumab (bTrastuzumab) and pegfilgrastim (bPegfilgrastim), with plans to expand the arrangement to include other...
By: Goodwin